Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.

"Declaration of interests BJC reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche, and Sanofi Pasteur. BJC has provided scientific advice to Pfizer and AstraZeneca on issues related to disease burden and vaccine effectiveness. He has not provided scientific advice to either company related to COVID-19 antiviral effectiveness, and he has not received any funding from Pfizer or AstraZeneca for any research on antiviral effectiveness including the current work. All other authors declare no competing interests."

"AcknowledgmentsAuthors would like to thank Kathy Leung for her input to oral antiviral drug prescription patterns and ascertainment rate of COVID-19 in Hong Kong, Eric Tang for statistical advice, and Xi Xiong for administrative and technical support. This study was supported by the Health and Medical Research Fund (COVID190210), Health Bureau, Government of Hong Kong Special Administrative Region, China."